The Patent Finder

Fundação Butantan

13 patents currently held · Updated Nov 18, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

1
Ending by 2030
Oct 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 18, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,827,299Selectively Disrupted Whole-Cell Vaccine
In force
 · High confidence
In forceHigh confidence
US 9,512,186Recombinant strain of Mycobacterium bovis bacillus calmette-guerin (BCG), immunogenic composition and use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,278,574Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,306,290Stem cells expressing mesenchymal and neuronal markers, compositions thereof, and methods of preparation thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,498,498Adipose tissue mesenchymal stem cells and methods of use to treat or inhibit uterine disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,480,095Multifunctional immature dental pulp stem cells and therapeutic applications
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,239,670Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,081,660Polynucleotide, Polypeptide with Immunosuppressive Activity, Expression Cassette, Expression Vector, Host Cell, Pharmaceutical Composition, Methods for Producing a Polypeptide with Immunosuppressive Activity and for Preventing or Treating Conditions That Require Immunosuppression, and Use of a Polypeptide
In force
 · High confidence
In forceHigh confidence
US 9,833,444Use of chemical compounds that can inhibit the toxic activity of sphingomyelinase D from venoms of Loxosceles spiders and pharmaceutical composition comprising said compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,207,352Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited